companies / phasevtrials-com
Generated UTC · publication cutoff 2026-11-09
Insufficient cited evidence for a two-sentence summary.
verified=2026-06-12 json
| total_raised | 65,000,00065.0M | ○ |
|---|---|---|
| founded | 2020 | |
| hq | Boston | |
| industry | unknown | |
| stage | series-a |
PhaseV provides AI and machine learning tools that streamline clinical drug development from trial design through execution and analysis. It serves biopharma sponsors and CROs across oncology, immunology, and neurology. Its edge is causal machine learning that finds responsive patient subgroups and enables smaller, faster, lower-cost trials.
No cited completed company acquisition recorded.
Dated disclosures. Customer relationships and classifications are historical; ARR is separate from revenue.
No cited disclosure recorded: named customer, disclosed revenue, ARR, count, B2B / B2C, sector, go-to-market.
No cited valuation with an explicit basis is recorded.
Historical post-money / actual annual or stated TTM revenue. Same currency; economic valuation date within 90 days of revenue period end, inclusive. No FX, ARR, annualized revenue, estimates or projections. Conflicts and ambiguous ties are withheld.
No qualifying pair recorded.
| date | type | amount | lead | src |
|---|---|---|---|---|
| 2025-05-13 | series-a | 50,000,00050.0M | null | ○ |
cloudflare, cookieyes, doubleclick floodlight, google analytics, google tag manager, hsts, http/3, jquery 3.5.1, jsdelivr, mysql, php, wordpress
| fact | status | src |
|---|---|---|
| Series A, $50.0M | attributed | ○ |
| existence | self-reported | WEB |
| description | self-reported | WEB |